Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of ORL-1M in Patients With CDG-Ib

Trial Profile

Study of ORL-1M in Patients With CDG-Ib

Phase of Trial: Phase I/II

Latest Information Update: 16 Oct 2018

At a glance

  • Drugs ORL-1M (Primary)
  • Indications Congenital disorders
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Orpha Labs
  • Most Recent Events

    • 04 Oct 2018 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
    • 04 Oct 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.
    • 25 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top